The FDA has granted marketing authorisation for Ofev, as the first treatment for patients with chronic fibrosing interstitial lung diseases (ILDs).
List view / Grid view
Filter the results
Ofev, which is under review for the treatment of people with chronic fibrosing interstitial lung diseases (ILDs), has been given Breakthrough Therapy Designation.
The FDA has approved the first treatment for interstitial lung disease associated with systemic sclerosis or scleroderma.